Anti-LHPL2/ LHFPL2 monoclonal antibody

Anti-LHPL2/ LHFPL2 antibody for FACS & in-vivo assay

Target products collectionGo to LHFPL2/LHFPL2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0727-Ab-1/ GM-Tg-hg-MP0727-Ab-2Anti-Human LHFPL2 monoclonal antibodyHuman
GM-Tg-rg-MP0727-Ab-1/ GM-Tg-rg-MP0727-Ab-2Anti-Rat LHFPL2 monoclonal antibodyRat
GM-Tg-mg-MP0727-Ab-1/ GM-Tg-mg-MP0727-Ab-2Anti-Mouse LHFPL2 monoclonal antibodyMouse
GM-Tg-cynog-MP0727-Ab-1/ GM-Tg-cynog-MP0727-Ab-2Anti-Cynomolgus/ Rhesus macaque LHFPL2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0727-Ab-1/ GM-Tg-felg-MP0727-Ab-2Anti-Feline LHFPL2 monoclonal antibodyFeline
GM-Tg-cang-MP0727-Ab-1/ GM-Tg-cang-MP0727-Ab-2Anti-Canine LHFPL2 monoclonal antibodyCanine
GM-Tg-bovg-MP0727-Ab-1/ GM-Tg-bovg-MP0727-Ab-2Anti-Bovine LHFPL2 monoclonal antibodyBovine
GM-Tg-equg-MP0727-Ab-1/ GM-Tg-equg-MP0727-Ab-2Anti-Equine LHFPL2 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0727-Ab-1/ GM-Tg-hg-MP0727-Ab-2; GM-Tg-rg-MP0727-Ab-1/ GM-Tg-rg-MP0727-Ab-2;
GM-Tg-mg-MP0727-Ab-1/ GM-Tg-mg-MP0727-Ab-2; GM-Tg-cynog-MP0727-Ab-1/ GM-Tg-cynog-MP0727-Ab-2;
GM-Tg-felg-MP0727-Ab-1/ GM-Tg-felg-MP0727-Ab-2; GM-Tg-cang-MP0727-Ab-1/ GM-Tg-cang-MP0727-Ab-2;
GM-Tg-bovg-MP0727-Ab-1/ GM-Tg-bovg-MP0727-Ab-2; GM-Tg-equg-MP0727-Ab-1/ GM-Tg-equg-MP0727-Ab-2
Products NameAnti-LHFPL2 monoclonal antibody
Formatmab
Target NameLHFPL2
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-LHFPL2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species LHPL2/ LHFPL2 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0727
    Target NameLHFPL2
    Gene ID10184,218454,294643,709040,610427,101081115,616131,106781664
    Gene Symbol and Synonyms6030465B15,LHFPL2,mKIAA0206,vgim
    Uniprot AccessionQ6ZUX7
    Uniprot Entry NameLHPL2_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000145685
    Target ClassificationN/A

    The target: LHFPL2, gene name: LHFPL2, also named as . This gene is a member of the lipoma HMGIC fusion partner (LHFP) gene family, which is a subset of the superfamily of tetraspan transmembrane protein encoding genes. Mutations in one LHFP-like gene result in deafness in humans and mice, and a second LHFP-like gene is fused to a high-mobility group gene in a translocation-associated lipoma. Alternatively spliced transcript variants have been found, but their biological validity has not been determined. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.